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The crucial role of HER2 in epithelial transformation and its selective overexpression on
cancer tissues makes it an ideal target for cancer immunotherapies such as passive
immunotherapy withTrastuzumab.There are, however, a number of concerns regarding the
use of monoclonal antibodies which include resistance, repeated treatments, considerable
costs, and side effects that make active immunotherapies against HER2 desirable alterna-
tive approaches.The efficacy of anti-HER2 DNA vaccination has been widely demonstrated
in transgenic cancer-prone mice, which recapitulate several features of human breast can-
cers. Nonetheless, the rational design of a cancer vaccine able to trigger a long-lasting
immunity, and thus prevent tumor recurrence in patients, would require the understand-
ing of how tolerance and immunosuppression regulate antitumor immune responses and,
at the same time, the identification of the most immunogenic portions of the target pro-
tein. We herein retrace the findings that led to our most promising DNA vaccines that, by
encoding human/rat chimeric forms of HER2, are able to circumvent peripheral tolerance.
Preclinical data obtained with these chimeric DNA vaccines have provided the rationale for
their use in an ongoing Phase I clinical trial (EudraCT 2011-001104-34).
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INTRODUCTION
The ability to drive the immune system’s powerful defense mecha-
nisms to act against cancer is more than just a theory as decades of
preclinical studies have demonstrated that the promise of cancer
vaccines is being realized. However, while the success of vaccina-
tion in preventing infectious diseases is uncontested, the derivation
of efficient vaccines against cancer is a more difficult challenge.
Although cancer cells express antigens in a way that immuno-
logically distinguishes them from normal cells, most tumors are
only weakly immunogenic because most tumor antigens are “self”
proteins which are generally tolerated by the host (Finn, 2003).
Thus, an effective cancer vaccine must activate the immune system
to react against tumor-associated molecules and, in some cases,
overcome immunological tolerance to such molecules. Moreover,
the increasing instability of transformed cells’ genomes favors the
emergence of low immunogenic clones that then no longer express
tumor antigens and finally, cancer cells elaborate many defenses
against immune attack. They attempt to become invisible to T
cells (Lollini and Forni, 2003) by decreasing the major histocom-
patibility complex (MHC) glycoproteins expression on their cell
membrane, and at the same time, suppress immune reactivity
via the direct release of transforming growth factor (TGF)-beta,
IL-10, and indoleamine 2,3-dioxygenase (IDO), and through the
activation of such secretions in myeloid-derived suppressor cells,
tumor-associated macrophages, and dendritic cells (DCs). As a
consequence, a tumor favors the activation and the expansion of
adaptive regulatory T (Treg) cells and therefore, the generation of a
tolerogenic environment (Cavallo et al., 2011). This ability to evade
immune recognition seems to increase as a tumor grows. In fact,
the promising results obtained with preventive cancer vaccines in
preclinical models are hard to reproduce with advanced cancers
when the immune system is already severely weakened. Advances
in cancer biology, an increasing knowledge of immune mecha-
nisms and the availability of new animal models that recapitulate
several human cancers have all helped to elucidate the critical
issues that influence the efficacy of the immune system’s attack
on cancer (Finn, 2003; Lollini et al., 2006; Cavallo et al., 2011).
Equally important for the rational design of cancer vaccines is the
development of new molecular strategies that are able to provide
cancer vaccines with the ability to stimulate the immune response
against established tumors, besides hampering cancer progression
when used at early stages of the disease.
DNA VACCINES
DNA vaccines offer distinct advantages over other vaccine proto-
types. They are stable, relatively inexpensive and simple to purify
in large quantities. Recombinant DNA technology allows for the
construction of DNA vaccines that encode selected tumor anti-
gens in their native forms or in a modified molecular format,
alone, or together with other molecules, to direct and amplify the
desired effector pathways. DNA vaccines are simple circles of DNA,
principally derived from bacterial plasmids, which contain cDNA
coding for the target antigen, a strong viral promoter to drive
the antigen expression in mammalian cells and a polyadenylation
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signal for transcription termination (Liu, 2003). The DNA vac-
cine is commonly delivered either via the biolistic system (Fynan
et al., 1993) or via simple intradermal or i.m. injections which
are commonly followed by a short in vivo electric pulse (elec-
troporation) to enhance DNA transfection by inducing tran-
sient biological membrane permeability (Bodles-Brakhop et al.,
2009). Once DNA vaccines enter mammalian cells, antigen syn-
thesis, and presentation occur (Liu, 2003). Professional antigen-
presenting cells (APCs), such as DCs, are able to present the
transcribed and translated antigen in the proper context of MHC
and costimulatory molecules, eliciting both cellular and humoral
responses. In addition, bacterial plasmids, unlike mammalian
DNA, are rich in unmethylated CpG dinucleotides which activate
the innate immune response by the binding with Toll-like receptor
9 expressed on B cells and APCs. Thus, DNA vaccines are effective
even when administrated without adjuvants (Krieg, 2002). How-
ever, chemokines and cytokines such as granulocyte-macrophage
colony-stimulating factor (GM-CSF) are commonly employed to
improve protection by DNA vaccines (Nguyen-Hoai et al., 2012).
CUTTING AND SEWING UP HER2: FROM CUT-DOWN TO
CHIMERIC DNA VACCINES
Antigen choice is the major determinant of a vaccine’s success.
The functional and structural characteristics of the tyrosine-kinase
receptor HER2 make it the perfect target for DNA vaccination
against cancer. Firstly, HER2 is a transmembrane (TM) receptor
that plays a causal role in oncogenic transformations, restricting
the emergence of antigen-loss variants. Secondly, HER2 overex-
pression in several aggressive course carcinomas, unlike its expres-
sion in normal tissues, ensures a specific anti-cancer response and
minimal risk of autoimmune attack on healthy tissues. Thirdly,
HER2 is exposed on the cell membrane and can thus be readily
targeted both by antibodies and cell-mediated immunity (Lollini
and Forni, 2003). Indeed, vaccines that target HER2, whether they
are designed as whole cells, peptides, or DNA expression plasmids,
are able to hamper cancer progression when used at early disease
stages (Ladjemi et al., 2010). In particular, DNA vaccines directed
against HER2 have proven to be successful in the prevention of
tumor growth in transplantable tumor models as well as in HER2
transgenic mice (Quaglino et al., 2004, 2005). The induction of
effective HER2 antitumor immunity seems to rely on a number of
mechanisms which depend on tumor model (Ursini-Siegel et al.,
2007). On the other hand, HER2 is a“self”molecule, therefore trig-
gering a stable and strong response to it must circumvent tolerance
mechanisms. Several different DNA vaccines have been generated
against HER2 thanks to recombinant DNA technology. A ratio-
nal dissection of the HER2 sequence led to the identification of
the most immunogenic portions of the molecule and, eventually,
of the crucial epitopes for the induction of immunoprotection.
These vaccines had mainly been tested in BALB-neuT mice which
are genetically predestined to develop lethal invasive mammary
carcinomas with 100% penetrance, high multiplicity (all mam-
mary glands are affected) and relatively short latency (Quaglino
et al., 2008). In these mice, the neoplastic transformation of the
mammary epithelium is due to the expression of the activated rat
HER2 (a mutated form with valine instead of glutamic acid at
residue 664 in the TM domain) in the mammary gland.
HER2 consists of an extracellular (EC) domain, a single TM-
spanning domain and a long cytoplasmic tyrosine-kinase domain.
The EC domain is about 630 amino acids long and contains four
sub-domains arranged as a tandem repeat of a two-domain unit
(Cho et al., 2003). In one of the first studies of HER2-targeted
DNA vaccination, it was demonstrated that removing the intra-
cellular domain of this protein and maintaining its TM anchorage
improved immunoprotection. In fact, the plasmid that encoded
the EC and TM domains of HER2 (Figure 1A) proved to be far
superior to plasmids that only encoded the EC domain (secreted
form) or the full-length protein (Amici et al., 2000). Most sub-
sequent studies, performed in both wild-type BALB/c mice and
cancer-prone BALB-neuT transgenic mice, confirmed the exis-
tence of this vaccine’s unique ability to trigger protective immunity
toward rat HER2-positive tumors (Rovero et al., 2000; Curcio et al.,
2003; Quaglino et al., 2004; Rolla et al., 2008). About 50% of BALB-
neuT mice that had been electroporated with the EC-TM plasmid
at 10 and 12 weeks of age, when the mammary glands displayed
atypical hyperplasia, remained free of autochthonous mammary
tumors up to at least 1 year of age, whereas all unvaccinated mice
succumbed to mammary cancer within 22–27 weeks (Quaglino
et al., 2004).
In order to identify the minimal EC portion of rat HER2 that
is still able to elicit protective immunity, sequential deletions of
multiples of 240 bp, corresponding to 80 amino acids, were carried
out starting from its NH2-terminal sequence (Rolla et al., 2008).
A first series of DNA vaccination experiments with the result-
ing seven cut-down plasmids was performed in wild-type BALB/c
mice transplanted with syngeneic rat HER2-positive adenocar-
cinoma cells established from a BALB-neuT mouse mammary
tumor (TUBO cells). Significant protection was obtained in mice
immunized with the first four cut-down plasmids, while pro-
tection declined in mice immunized with shorter fragments. In
particular, EC4-TM (Figure 1B), which lacks almost half of the EC
domain and exposes only 344 amino acids, protected all vaccinated
mice through the induction of anti-rat HER2 antibodies at levels
comparable to those in mice vaccinated with the whole EC-TM
(Rolla et al., 2008). However, in wild-type BALB/c mice, vacci-
nation triggered a strong immune response because the rat HER2
protein target is a foreign, xenogeneic antigen differing in less than
6% of amino acids from mouse HER2. This immune protection is
much more difficult to achieve in cancer-prone BALB-neuT mice,
which are tolerant to rat HER2 protein because they express the
transgene protein product in their thymus early in life, and for this
reason they completely lack T cells that recognize dominant epi-
topes with high affinity (Rolla et al., 2006, 2010). The progression
of the autochthonous rat HER2-positive lesions is accompanied
by rampant immunosuppression due to the expansion of Treg
cells and immature myeloid cells (Ambrosino et al., 2006). In
those mice, only electroporation with EC4-TM hampered BALB-
neuT autochthonous mammary carcinogenesis, extended tumor-
free survival, and reduced tumor multiplicity, whereas the other
cut-down plasmids were completely ineffective. This remarkable
protection was not different from that afforded by the EC-TM plas-
mid and correlated with the induction of anti-rat HER2 antibodies
(Rolla et al., 2008). Interestingly, EC4-TM induced a stronger
antibody-dependent cell-mediated cytotoxicity (ADCC) response
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FIGURE 1 | Maps of anti-HER2 DNA vaccines. pVAX1 (3.0 kb) (Invitrogen)
was used as a backbone. The vectors contain the following elements: human
cytomegalovirus immediate-early (CMV) promoter (green) for high-level
expression in a wide range of mammalian cells; bovine growth hormone
(BGH) polyadenylation signal (yellow) for efficient transcription termination
and the polyadenylation of mRNA; kanamycin resistance gene (purple) for
selection in E. coli ; and the origin of bacterial replication (pUC ori, light blue).
pVAX-EC-TM (A): the cDNA (about 2 kb) that encodes the extracellular (EC)
and transmembrane (TM) domains of rat HER2 was cloned into pVAX1 using
HindIII and XbaI restriction enzymes. pVAX-EC4-TM (B): the cDNA that
encodes a truncated form of rat HER2, which displays an EC domain that was
shortened by 310 NH2-terminal residues and a TM domain, was inserted into
pVAX1 using EcoRI and XbaI restriction enzymes, downstream of the leader
sequence that had been previously cloned with HindIII and EcoRI. RHuT (C):
rat cDNA that encodes the 410 NH2-terminal residues of HER2 was cloned
into pVAX1 using HindIII and BstEII restriction enzymes upstream of the
human cDNA that encodes the remaining residues of the EC and the TM
domains previously cloned using BstEII and XbaI restriction enzymes.
pVAX-EC-TM-siRNA (D): a silencing module, which generates a short hairpin
(sh)RNA under the control of a polymerase III promoter was inserted into
pVAX-EC-TM. The interference cassette is composed of the pH1 or pU6
promoter upstream of an insert that specifies a 19–21-nt sequence derived
from the target transcript, separated by a short spacer (6–9 nt) from the
reverse complement of the same 19–21 nt sequence.
than the whole EC-TM, suggesting that EC4-TM provides acces-
sible critical determinants that may be partially masked in the
whole EC-TM (Rolla et al., 2008). Together, these results led to
the conclusion that; (i) the first 390 rat HER2 amino acids are
those responsible for triggering the protective immunity induced
by EC-TM vaccination, (ii) the main mechanism responsible for
the antitumor response is represented by anti-rat HER2 antibody
production, (iii) the immune protection elicited by DNA vac-
cines that encode the full-length or truncated HER2 is doomed
to decline in tolerant BALB/neuT mice and carcinogenesis is no
longer controlled about 3 months after each vaccination course.
Since immunological tolerance against HER2 represents a bar-
rier to effective vaccination against this oncoprotein, the next
challenge in the generation of anti-HER2 cancer vaccines is
the development of molecular strategies aimed at breaking this
tolerance to the HER2 self-antigen.
To further improve the elicited protection, two new chimeric
DNA vaccines (RHuT and HuRT) were constructed by combining
the two advantages of specificity, ensured by syngeneic portions,
and tolerance break, ensured by xenogeneic portions, all in one
molecule (Jacob et al., 2010; Quaglino et al., 2010, 2011). In par-
ticular, HuRT was derived by cloning the human cDNA fragment
that encodes the first 390 NH2-terminal residues into the rat EC5-
TM cut-down plasmid to regenerate the whole EC domain. Almost
symmetrically, RHuT (Figure 1C) encodes a protein in which
the 410 NH2-terminal residues are from the rat HER2 and the
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remaining residues from human HER2. Chimeric vaccines dis-
played superior performance in tolerant BALB-neuT mice (Jacob
et al., 2010; Quaglino et al., 2010, 2011). While control mice vac-
cinated with empty pVAX plasmid developed rat HER2-positive
mammary tumors within 27 weeks of age, all mice that had been
electroporated at 10 and 12 weeks of age with RHuT or fully rat EC-
TM remained tumor-free at 40 weeks. However, 10 weeks later, the
protection of mice vaccinated with rat EC-TM decreased to about
50%, while 80% of RHuT vaccinated mice remained completely
tumor-free. In both cases, the tumor rejection pattern correlated
with high titers of anti-rat HER2 antibodies. In addition, repeated
boosting of RHuT vaccination to maintain immunological mem-
ory allowed to significantly extend tumor protection (Quaglino
et al., 2010). Interestingly, the optimal response was elicited when
the NH2-terminal portion of the chimeric protein and the corre-
sponding portion on the targeted HER2 ortholog were identical.
This quality seems to be an almost absolute requirement whose
importance goes beyond the chimeric benefit.
CLINICAL TRIALS
The anti-HER2 DNA vaccines have now entered the clinical phase,
although only a few Phase I clinical trials are under way. Among
them, one is ongoing to evaluate the side effects and identify the
best dose of RHuT delivered using electroporation in patients
treated for primary Stage III/IV ErbB-2+ carcinomas of the oral
cavity, oropharynx, and hypopharynx (EudraCT number: 2011-
001104-34). In this study, whose enrollment is still ongoing, DNA
vaccination has been proposed without adjuvants or combined
therapies. Two other clinical trials are studying the toxicity and
efficiency of a DNA vaccine coding for the HER2 intracellular
domain when given together with GM-CSF (ClinicalTrials.gov,
NCT00436254) or before immunization with a vaccine made from
HER2/neu protein (ClinicalTrials.gov, NCT00363012) in patients
with stage III-IV breast cancer or ovarian cancer. However, the
first administration of a DNA vaccine encoding HER2 in humans
was in a pilot clinical trial of patients with metastatic HER2-
expressing breast carcinoma who were also being treated with
trastuzumab (Norell et al., 2010). The vaccine used in this study
was a pVAX encoding a full-length signaling-deficient version of
the oncogene HER2 and was administered together with low doses
of GM-CSF and IL-2. This clinical trial demonstrated that the
anti-HER2 DNA vaccine was safe, well tolerated after i.m. and
intradermal administration and could induce long-lasting cellular
and humoral immune responses against HER2 in patients with
advanced breast cancer (Norell et al., 2010).
HUNTING CRUCIAL HER2 EPITOPES
The generation of an effective vaccine against cancer entails the
development and use of new biotechnological tools for the iden-
tification of the most immunogenic portions of a target molecule
and for the selection of the key epitopes within an oncogenic
protein. Considering the fundamental roles of conformational
epitopes in effective immunological responses, we engineered a
phage-displayed collection of HER2 fragments, that we called
Large Fragment Phage Display (LFPD), that reproduces HER2
conformational epitopes (Figure 2A) (Gabrielli et al., 2013). The
LFPD was screened using the sera obtained from BALB/c and
BALB-neuT mice immunized with the EC-TM plasmid. The
screening with sera of BALB/c mice permitted conformational
epitopes that correspond to fragments rat1, rat2, rat9, and rat11 to
be identified (Figure 2B). This result was confirmed using the sera
obtained from BALB-neuT mice, although with a lower reactivity.
In addition, sera from mice vaccinated with the EC4-TM truncated
form of rat HER2, showed strong reactivity for fragment rat6, as
well as for rat9 and rat11 and, as expected, ignored the first part of
the molecule (Figure 2B). The strong reactivity toward rat6 may
be explained by an immunodominant effect caused by epitopes
that might be present in the first part of the molecule (Gabrielli
et al., 2013). Remarkably, all the conformational epitopes recog-
nized by the polyclonal antibodies present in the sera of vaccinated
mice corresponded to the epitopes predicted by PEPITO software
analysis (Figure 2C). In order to selectively induce an immune
response against rat2, rat6, rat9, and rat11 HER2 epitopes, we
developed DNA vaccines that code for fusion proteins between
the murine Fc-region of an IgG2a molecule that acts as molecular
support for correct protein folding and each single rat HER2 con-
formational epitope. Since a TM domain was inserted in each DNA
vaccine, the selected antigens were exposed on the cell surface.
Preliminary results demonstrate that these epitope-based vaccines
are able to induce immune protection against transplanted rat
HER2-overexpressing tumors in BALB/c mice, demonstrating that
antibodies raised against the selected epitopes can recognize the
native rat HER2 protein (Gabrielli et al., 2013). This molecular
approach opens the way for the generation of new and poten-
tially more effective B-cell conformational epitope-based vaccines,
in which a rational combination of selected xenogeneic and syn-
geneic epitopes may well lead to an optimization of the immune
response.
TURNING OFF NETWORK CONNECTIONS: IMPLICATIONS
FOR VACCINE DESIGN
Dendritic cells play a critical role in immunity and tolerance (Hart,
1997; Steinman and Inaba, 1999). Tumor-induced modulation of
DCs function is one of the main causes of tumor immune escape.
Tumors produce a range of immunosuppressive molecules which
expand or recruit tolerogenic DCs and Treg cells, resulting in the
suppression of innate and adaptive immune responses (Jarnicki
et al., 2006; von Bergwelt-Baildon et al., 2006). DCs in tumors
have limited antigen-presenting function. Inefficient antigen pre-
sentation extends to the tumor-draining lymph node and may
affect the generation of effective antitumor immune responses
(Stoitzner et al., 2008). A new kind of anti-HER2 DNA vaccine
has recently been developed as part of a strategy aimed at revert-
ing the immunosuppressive circuits that undermine an effective
antitumor immune response. It combines antigen expression with
the silencing of immunosuppressive molecules that are responsi-
ble for the tolerogenic behavior of DCs (Figure 1D). This double
action is associated with two distinct modules; one is the con-
ventional antigen expression cassette, while the other generates
specific short hairpin (sh)RNA against an immunosuppressive
molecule under the control of a polymerase III promoter (Yen
et al., 2009). The interference cassette is usually composed of
the pol III promoter (H1 or U6), upstream of an insert that
specifies a 19–21 nt sequence derived from the target transcript,
separated by a short spacer (6–9 nt) from the reverse comple-
ment of the same 19–21 nt sequence (Brummelkamp et al., 2002).
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FIGURE 2 | Identification of relevant conformational epitopes on
the HER2 oncoprotein by LFPD. LFPD structure (A). The EC domain
of rat HER2 was divided into 11 fragments of 106 amino acids: 6
contiguous core fragments+5 fragments that overlap the previous
ones. Screening of sera from mice vaccinated with EC-TM plasmid by
an ELISA assay based on LFPD (B). Both sera from BALB/c (blue line)
and BALB-neuT (red line) mice recognized rat1 (1–106 aa), rat2
(107–216 aa), rat9 (267–376 aa), and rat11 (487–596 aa)
conformational epitopes, although tolerant mice sera showed lower
reactivity. Sera from mice vaccinated with a truncated form of HER2
(EC4-TM) recognized rat6 (547–656 aa), rat9, and rat11 fragments
(orange line). Pepito based analysis of rat HER2 (C). Red zones
indicate the maximum probability of finding a conformational epitope.
Adapted from Gabrielli et al. (2013).
The resulting transcript folds back on itself to form a 19 to 21
base pair stem-loop structure. These shRNA structures can be
processed by the endogenous endoribonuclease Dicer to generate
short interfering (si)RNAs that specify RNA interference process
ending with the sequence-specific degradation of messenger RNA
(Brummelkamp et al., 2002). RNA interference with the synthesis
of negative immune regulators, such as IDO or IL-10, is expected
to ensure optimal presentation of the encoded antigen by APCs.
CONCLUSION
Cancer vaccines can be designed to prepare the immune system to
fight cancer. The choice of the target antigen is the first step to take
into account for the generation of a promising cancer vaccine. It
is possible to construct multi-task vaccines to improve elicited
protection and this is done by combining the most immuno-
genic portions of a target antigen with molecules that help the
immune response, all in one plasmid. However, this technical
process is not enough to ensure the success of a vaccine. Cancer
vaccines must overcome any immune suppression exerted by the
tumor, must break immune tolerance against target antigens and
elicit long-term memory, but at the same time they must avoid
detrimental autoimmune reactions and as such, the therapeutic
schedule, the timing and doses of drug administration are also of
crucial importance.
The number of specific strategies we described to generate
DNA vaccines against HER2 might be translatable to other vac-
cines against different target molecules opening the way for the
generation of new conceived immunological tools.
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